What is Biodel?
Biodel Inc. operates as a specialized biopharmaceutical entity dedicated to the advancement and commercialization of innovative treatments for diabetes. The company distinguishes itself through the application of proprietary formulation technologies to existing pharmaceutical compounds, effectively optimizing their therapeutic profiles. By focusing on safety, convenience, and improved patient outcomes, Biodel addresses critical gaps in current diabetes management protocols. Its market position is defined by a commitment to refining drug delivery mechanisms, thereby creating value through intellectual property and clinical differentiation in a high-demand therapeutic sector.
How much funding has Biodel raised?
Biodel has raised a total of $105M across 2 funding rounds:
Stock Offering
$75M
Unspecified
$30M
Stock Issuance/Offering (2007): $75M, investors not publicly disclosed
Unspecified (2011): $30M led by OrbiMed and Great Point Partners
Key Investors in Biodel
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Great Point Partners
Great Point Partners is a leading healthcare investment firm providing growth equity and management buyout financing, with a specific emphasis on biopharmaceutical services, pharmaceutical infrastructure, and healthcare IT.
Undisclosed Investors
What's next for Biodel?
Looking ahead, the strategic deployment of the $30M will likely focus on scaling operational capabilities and advancing late-stage clinical trials. As the company transitions through this major enterprise-level funding phase, the primary objective remains the successful regulatory navigation and eventual market entry of its core product candidates. Investors are closely monitoring the company's ability to translate its formulation expertise into tangible commercial success, particularly as it seeks to disrupt the standard of care for diabetic patients. Future growth will be contingent upon the firm's capacity to maintain its research momentum while effectively managing the capital-intensive nature of biopharmaceutical development.
See full Biodel company page
